In the 1940s the “British Technology Group” was set up by the UK government to commercialise inventions from UK universities and the newly-formed NHS. BTG was the original “tech transfer office,” helping to commercialise technology ranging from agricultural equipment to mobile phones. We made notable contributions to the medical field, helping bring to market the MRI, cephalosporin antibiotics, interferon, cholesterol assay tests, and three-part knee replacements among other inventions.
In 1992 the group was spun out of government and took on the name BTG plc when it was publicly listed in ’95. Following a strategic review in 2005, BTG plc focused on life sciences and began investing in specialty pharmaceuticals, notably through the acquisition of Protherics, another listed UK company, and establishment of a commercial and medical infrastructure in the US.
For several years BTG plc focused on minimally invasive procedures growing out of advances in medical imaging technology. BTG invested in a portfolio of devices to treat patients with cancer, vascular disease, and emphysema. In 2019 BTG plc was acquired by Boston Scientific, a global medical technology leader. In 2021 Boston Scientific divested BTG Specialty Pharmaceuticals.
Today BTG Specialty Pharmaceuticals is part of SERB Specialty Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®. These products are sold primarily in the United States through internal sales, marketing, The company has best-in-class capabilities in polyclonal antibody development and manufacturing with facilities in Wales, Australia, and Utah.
In 1992 the group was spun out of government and took on the name BTG plc when it was publicly listed in ’95. Following a strategic review in 2005, BTG plc focused on life sciences and began investing in specialty pharmaceuticals, notably through the acquisition of Protherics, another listed UK company, and establishment of a commercial and medical infrastructure in the US.
For several years BTG plc focused on minimally invasive procedures growing out of advances in medical imaging technology. BTG invested in a portfolio of devices to treat patients with cancer, vascular disease, and emphysema. In 2019 BTG plc was acquired by Boston Scientific, a global medical technology leader. In 2021 Boston Scientific divested BTG Specialty Pharmaceuticals.
Today BTG Specialty Pharmaceuticals is part of SERB Specialty Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®. These products are sold primarily in the United States through internal sales, marketing, The company has best-in-class capabilities in polyclonal antibody development and manufacturing with facilities in Wales, Australia, and Utah.